The Specialty Pharmacy Review BoardTM - Examining Emerging Therapies and Care Management Interventions for Alzheimer's Disease

You Are Invited to a One-time LIVE CME/CPE Webcast on

Tuesday, April 18, 2017 from 1:00 PM to 2:30 PM ET


The Specialty Pharmacy Review Board™ - Examining Emerging Therapies and Care Management Interventions for Alzheimer's Disease


Jointly provided by
Impact Education, LLC    
This activity is supported by independent educational grants from Avanir Pharmaceuticals, Inc. and Lilly USA, LLC. For further information concerning Lilly grant funding visit www.LillyGrantOffice.com.




On-demand Archive Coming Soon!

HOT TOPICS
  • Impact of care coordination in Alzheimer's disease (AD)
  • Novel mechanisms of action (MOAs) and clinical benefits of emerging disease-modifying agents
  • Benefit design strategies for emerging biologic and small-molecule AD therapies
  • Role of specialty pharmacy in supporting appropriate utilization and administration of emerging therapies
DISTINGUISHED FACULTY PRESENTERS
Steven Avey, MS, RPh, FAMCP
Vice President, Specialty Pharmacy
MedImpact Healthcare Systems, Inc.
John Fox, MD, MHA
Senior Medical Director
Associate Vice President
Medical Affairs
Priority Health
James Kenney, Jr., RPh, MBA
Manager, Specialty and Pharmacy Contracts
Harvard Pilgrim Health Care
Marwan Sabbagh, MD, FAAN, CCRI
Karsten Solheim Chair for Dementia
Professor of Neurology
Director of the Alzheimer's and Memory Disorders Division
Barrow Neurological Institute
WHO SHOULD ATTEND?

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, pharmacy directors, specialty pharmacists, quality directors, care managers, and other managed care and payer organization professionals.

STATEMENT OF NEED / PROGRAM OVERVIEW

Alzheimer's disease (AD) represents a significant driver of morbidity and mortality in the US, despite being overshadowed by other predominant conditions for which more effective treatment modalities exist. The incidence and mortality associated with the disease is increasing, indicating a key area of concern for managed care stakeholders. An estimated 5.3 million Americans were living with AD in 2015, and as many as 7.1 million will be diagnosed with the disease by 2025 according to the Alzheimer's Association. By 2050, that number may nearly triple to a projected 13.8 million, barring the development of medical breakthroughs to prevent or cure the disease. Unsurprisingly, this considerable burden of illness associated with AD is also accompanied by extensive direct and indirect costs.

This symposium will feature a multidisciplinary faculty panel who will present best practices for implementing collaborative treatment and patient management decisions that lead to optimal outcomes for patients with AD. This approach will enhance the audiences' ability to recommend and implement payer specific techniques to improve the continuity of care related to the impact of AD management strategies on clinical outcomes, value, and economic consequences for the entire health care system. The Specialty Pharmacy Review Board™ format will be similar to a mock pharmacy and therapeutics committee meeting, featuring an expert panel including a leading neurologist in AD research and practice, a specialty pharmacy director, and managed care medical and pharmacy directors.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Describe various diagnostic tools for AD and evaluate their respective benefits and disadvantages for standardized use among network providers
  • Describe the impact of care coordination in AD in terms of patient quality of life and disease outcomes
  • Implement plan-wide initiatives to better coordinate care for AD among primary and ancillary providers in acute and long-term settings
  • Appraise the novel mechanism of action (MOAs) and clinical benefits of emerging disease-modifying agents for the management of AD
  • Recommend benefit design strategies for emerging biologic and small-molecule AD therapies that encourage appropriate utilization while facilitating patient access and adherence
  • Outline the components and benefits of an effective medication therapy management (MTM) program for AD
  • Characterize the role of specialty pharmacy in supporting appropriate utilization and administration of emerging therapies for AD
AGENDA
Pre-Activity Learning Assessment and Opening Comments
James Kenney, Jr., RPh, MBA
Assessing the Clinical Benefits and MOAs for Emerging Therapies
Marwan Sabbagh, MD, FAAN, CCRI
Care Coordination Strategies to Enhance Patient Outcomes Across the Continuum of Disease Management
John Fox, MD, MHA
Medical and Pharmacy Benefit Design Strategies for Emerging Therapies
James Kenney, Jr., RPh, MBA
Pharmacosurveillance and Patient/Caregiver Counseling Approaches to Minimize Medication Errors and Enhance Appropriate Utilization
Steven Avey, MS, RPh, FAMCP
Audience Question and Answer Session
Key Takeaways and Closing Comments
Post-activity Assessment and Evaluation
ACCREDITATION INFORMATION
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Medical Education Resources, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - 0816-9999-17-089-L01-P

Type of Activity: Knowledge

Nursing Continuing Education
Accreditation Statement

Medical Education Resources, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.5 contact hours of continuing nursing education.

Medical Education Resources, Inc. is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, and certifies this activity for 1.5 contact hours.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.